Detalhe da pesquisa
1.
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
J Immunother
; 41(9): 399-405, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29757889
2.
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Clin Cancer Res
; 24(18): 4416-4428, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848573
3.
A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.
Front Immunol
; 8: 908, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28824634
4.
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.
Cancer Immunol Res
; 3(11): 1201-6, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26216417
5.
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
Clin Cancer Res
; 18(19): 5329-40, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22850568
6.
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Clin Cancer Res
; 18(24): 6758-70, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23032743
7.
Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Vaccine
; 25(17): 3302-10, 2007 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-17291642